bmcgastroenterol.biomedcentral.com
Fecal calprotectin from ileostomy output in patients with Crohn's disease | BMC Gastroenterology
People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative inflammation and guide follow-up decisions.
Patients with Crohn’s disease and an ileostomy; gastroenterologists and surgeons who manage postoperative IBD; researchers studying IBD biomarkers.
What To Know
What to know This study looked at whether fecal calprotectin (FC) measured from ileostomy output can help detect small-bowel inflammation after surgery in people with Crohn’s disease.
The researchers compared FC results from point-of-care (POC) tests and ELISA with imaging and/or ileoscopy findings in a retrospective cohort and found higher FC levels when imaging/endoscopy showed inflammation.
The paper reports that FC from ileostomy output showed good sensitivity and specificity for detecting postoperative small-bowel inflammation and compares performance between ELISA and rapid POC tests. This was a single-center, retrospective analysis of patients with ileostomy who had paired FC and imaging/endoscopic assessments.
Who should pay attention Patients with Crohn’s disease who have an ileostomy, clinicians who follow postoperative IBD patients, and researchers studying noninvasive biomarkers for surgical recurrence will find this study relevant.
More context This is retrospective single-center research; it suggests FC from ileostomy output may be a useful noninvasive monitoring tool but does not establish clinical practice guidelines or change treatment by itself.
Differences between assays (ELISA vs POC) and the study population (postoperative ileostomy patients) are important when interpreting applicability.
Retrospective single-center study comparing FC from ileostomy output to imaging and/or ileoscopy. Findings support FC as a sensitive marker but require validation in larger, prospective cohorts and consideration of assay differences (ELISA vs POC) before changing practice.
